PT-141 vs Kisspeptin-10
Both PT-141 and Kisspeptin-10 are used for sexual-health. Here's how their evidence, dosing, and regulatory status actually compare.
PT-141
Evidence ABremelanotide (Vyleesi)
A melanocortin receptor agonist that works directly on the nervous system to increase sexual desire. The only FDA-approved peptide for sexual dysfunction that acts on the brain rather than vascular system.
View full PT-141 profile →Kisspeptin-10
Evidence BKisspeptin-10 (KP-10)
A 10-amino-acid neuropeptide that triggers GnRH release. Studied as a more physiologic alternative to hCG/GnRH for fertility, libido, and HPG-axis assessment.
View full Kisspeptin-10 profile →Side-by-Side
| Attribute | PT-141 | Kisspeptin-10 |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | FDA-approved for hypoactive sexual desire disorder (HSDD) in women | Not FDA-approved — used in clinical research as a kisspeptin/GnRH stimulus test |
| Typical Dose | 1.75 mg subcutaneous, 45 min before activity | Trial range: 0.1–10 mcg/kg IV/SC bolus |
| Clinics Indexed | 210 | 11 |
| Categories | sexual-health | sexual-health, fertility |
Key reported benefits — PT-141
- ✓Increased sexual desire
- ✓CNS-mediated arousal
- ✓Works for both sexes (off-label for men)
Key reported benefits — Kisspeptin-10
- ✓GnRH/LH/FSH stimulation
- ✓Libido/arousal effects
- ✓HPG-axis testing
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.